Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere dysfunction is implicated in the generation of large‐scale genomic rearrangements that drive progression to malignancy. In this study we used high‐resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) an...

Descripció completa

Dades bibliogràfiques
Autors principals:	Williams, J, Heppel, N, Britt-Compton, B, Grimstead, J, Jones, R, Tauro, S, Bowen, D, Knapper, S, Groves, M, Hills, R, Pepper, C, Baird, D, Fegan, C
Format:	Journal article
Idioma:	English
Publicat:	Wiley 2017

Ítems similars

Telomere length is a critical determinant for survival in multiple myeloma
per: Hyatt, S, et al.
Publicat: (2017)

Maintenance of telomere length in AML
per: Peter M. Lansdorp
Publicat: (2017-11-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
per: Nadia El Menshawy, et al.
Publicat: (2020-07-01)

Inherited predisposition to MDS/AML
per: Ana Rio Machin, et al.
Publicat: (2018-06-01)

Telomerase activity and telomere length in AML-M3 patients
per: Hamidollah Ghaffari, et al.
Publicat: (2009-04-01)

Telomerase activity and telomere length in AML-M3 patients
per: Hamidollah Ghaffari, et al.
Publicat: (2009-06-01)

T cell memory revisited using single telomere length analysis
per: Laureline Roger, et al.
Publicat: (2023-09-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
per: Barbara De Moerloose
Publicat: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
per: Theilgaard-Mönch, K, et al.
Publicat: (2011)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
per: Olga K. Weinberg, et al.
Publicat: (2023-08-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
per: Hoyle, C, et al.
Publicat: (1989)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
per: Goh, Chermaine Yu Zhen
Publicat: (2021)

p53 biology and reactivation for improved therapy in MDS and AML
per: Joanna E. Zawacka
Publicat: (2024-03-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
per: V. Sheth, et al.
Publicat: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
per: A. G. Lema Fernandez, et al.
Publicat: (2022-06-01)

PERFORMANCE OF CYTOGENETIC TESTS IN AML AND MDS SAMPLES PROCESSED IN A REMOTE LABORATORY IN BRAZIL
per: A Amaro, et al.
Publicat: (2024-10-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
per: Petra Bašová, et al.
Publicat: (2025-01-01)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
per: Udit Bhaskar Bhatnagar, et al.
Publicat: (2016-01-01)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
per: Azra Raza, et al.
Publicat: (2020-01-01)

Telomere length in myelodysplastic syndromes.
per: Boultwood, J, et al.
Publicat: (1997)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
per: Christoforos K. Vaxevanis, et al.
Publicat: (2023-12-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
per: YE Xiangjun, LU Xingguo
Publicat: (2023-10-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
per: V. Van Oorschot, et al.
Publicat: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
per: Hongjiao Li, et al.
Publicat: (2023-09-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
per: Lixian Chang, et al.
Publicat: (2022-09-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
per: Guancui Yang, et al.
Publicat: (2022-10-01)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
per: Barreyro, L, et al.
Publicat: (2012)

TELOMERE LENGTH AND ATHEROSCLEROSIS
per: O. M. Drapkina, et al.
Publicat: (2016-09-01)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
per: Anson Snow, et al.
Publicat: (2022-07-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
per: Zuzana Tothova, et al.
Publicat: (2021-02-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
per: T. Ueda, et al.
Publicat: (2024-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
per: A. Shastri, et al.
Publicat: (2024-01-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
per: Sandra Huber, et al.
Publicat: (2023-08-01)

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
per: Laura Barreyro, et al.
Publicat: (2024-06-01)

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
per: Victoria V. Grunwald, et al.
Publicat: (2019-09-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
per: Amer M. Zeidan, et al.
Publicat: (2024-06-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
per: Tahsin Anwar, et al.
Publicat: (2023-12-01)

Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS
per: Peter Vandenberghe, et al.
Publicat: (2011-06-01)

Telomere length in myelodysplastic syndromes.
per: Boultwood, J, et al.
Publicat: (1995)

Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
per: Rongtao Xue, et al.
Publicat: (2025-02-01)